<DOC>
	<DOCNO>NCT00701168</DOCNO>
	<brief_summary>The purpose protocol provide supervise limited access Therasphere® treatment patient primary liver cancer chemotherapy refractory liver metastasis treat surgical removal affect part liver . Patient response treatment side effect Therasphere® treatment examine .</brief_summary>
	<brief_title>Therasphere® Treatment Unresectable Primary Liver Cancer Metastatic Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Confirmed diagnosis primary metastatic intrahepatic carcinoma The cancer must unresectable limited establish treatment option ECOG Performance Status Score 02 Age 19 year older Able comprehend provide write informed consent Any pretreatment laboratory finding within 15 day treatment demonstrating : Absolute granulocyte count ≤ 1,500/ul Platelet count ≤ 75,000/ul Serum creatinine &gt; 2.0 mg/dl Serum bilirubin ≥ 2.0 mg/dl Any follow contraindication angiography selective visceral catheterization : History severe allergy intolerance contrast medium , narcotic , sedative , atropine Bleeding , diathesis , correctable usual form therapy Severe peripheral vascular disease would preclude catheterization Substantial venous shunt away liver Evidence potential delivery great 11 mCi ( 20 Gy absorb dose ) radiation lung either 1 ) first Therasphere® administration ; 2 ) cumulative delivery radiation lung multiple treatment Evidence detectable Tc99 MAA flow stomach duodenum , application establish angiographic technique stop flow Significant extrahepatic disease represent imminent life threaten situation outcome Severe liver dysfunction pulmonary insufficiency Active uncontrolled infection Significant underlying medical psychiatric illness Pregnant woman may participate</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>